Examples of using Clinical development program in English and their translations into Portuguese
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Official/political
Mitotane has not been studied in a comprehensive clinical development program.
The clinical development program was composed by 5 studies provided in the following table.
The qHPV vaccine was used as an active control during the clinical development program for Gardasil 9.
During the clinical development program, 3,315 women(vaccine 1,657 vs. placebo 1,658) reported at least one pregnancy.
Safety of ulipristal acetate has been evaluated in 4,718 women during the clinical development program.
The clinical development program has included over 1,900 patients, with different types of epilepsy, exposed to rufinamide.
No cases of overdose after cutaneous use of Mirvaso were reported during the clinical development program.
The Phase III clinical development program for Kuvan included 2, randomised placebo-controlled studies in patients with PKU.
The safety profile of Spedra is based on 2436 subjects exposed to avanafil during the clinical development program.
In the asthma clinical development program a total of 7,034 patients were included in an integrated assessment of adverse reactions.
The safety profile of ANORO is based on safety experience with umeclidinium/vilanterol andthe individual components from the clinical development program comprising of 6,855 patients with COPD and from spontaneous reporting.
However, during the clinical development program, a total of 10,476 pregnancies were reported including 5,387 in women who had received Cervarix.
The safety profile of LAVENTAIR is based on safety experience with umeclidinium/vilanterol andthe individual components from the clinical development program comprising of 6,855 patients with COPD and from spontaneous reporting.
During the clinical development program, the occurrence of cases of melanoma prompted the consideration of a possible association with rasagiline.
In conclusion, the IR of total malignancy breast, colorectal and lung cancers andlymphoma in the ABT clinical development program was consistent with that of a population with RA not using ABT, although data require further monitoring.
During the clinical development program(N=3,063), hepatitis was reported in 0.5% of patients receiving combination antiretroviral therapy with PREZISTA/ritonavir.
To obtain information on the occurrence of malignancies in patients with RA being treated with abatacept ABT,data from the ABT clinical development program were compared with those of other patients with RA and of the general population.
During the pre-licensure clinical development program, a total of 1,737 pregnancies were reported including 870 in women who had received Cervarix.
The overall rate and pattern of adverse events, study drug discontinuation due to AEs, andthe number of deaths reported in these clinical studies were consistent with those observed during the clinical development programs for the lyophilised formulation.
The highest reported overdose in the clinical development program for lacosamide was 12 g taken in conjunction with toxic doses of multiple other antiepileptic drugs.
The clinical development program consisted of two 8-week intravenous induction studies(UNITI-1 and UNITI-2) followed by a 44 week subcutaneous randomized withdrawal maintenance study(IM-UNITI) representing 52 weeks of therapy.
The overall safety profile of Xadago is based on the clinical development program performed in over 3000 subjects, of whom over 500 were treated for more than 2 years.
During the clinical development program(N=3,063), severe skin reactions, which may be accompanied with fever and/or elevations of transaminases, have been reported in 0.4% of patients.
During the clinical development program(N=2,613 treatment-experienced subjects who initiated therapy with PREZISTA/ritonavir 600/100 mg twice daily), 51.3% of subjects experienced at least one adverse reaction.
During the clinical development program of raltegravir in treatment-experienced patients, rash, irrespective of causality, was more commonly observed with regimens containing PREZISTA+ raltegravir compared to those containing PREZISTA without raltegravir or raltegravir without PREZISTA.